
5.90.050

Section:	Prescription Drugs	Effective Date:	July 1, 2024
Subsection:	Topical Products	Original Policy Date:	October 22, 2021
Subject:	Opzelura	Page:	1 of 9

Last Review Date: June 13, 2024

Opzelura

Description

Opzelura (ruxolitinib)

Background

Opzelura (ruxolitinib) is indicated for the topical treatment of mild to moderate atopic dermatitis and nonsegmental vitiligo. Atopic dermatitis, a chronic inflammatory skin disease, is often referred to as "eczema," which is a general term for the several types of inflammation of the skin. Atopic dermatitis is the most common of the many types of eczema and onset typically begins in childhood and can last through adulthood. The cause of atopic dermatitis is a combination of genetic, immune and environmental factors. Opzelura is a topical Janus kinase (JAK) inhibitor. Janus kinases (JAK1 and JAK2) are involved in a signaling cascade that recruits signal transducers and activators of transcription (STATs) to the nucleus leading to modulation of gene expression for many pathways including immune function (1).

Regulatory Status

FDA-approved indications: Opzelura is a Janus kinase (JAK) inhibitor indicated for (1):

- the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Section:	Prescription Drugs	Effective Date:	July 1, 2024
Subsection:	Topical Products	Original Policy Date:	October 22, 2021
Subject:	Opzelura	Page:	2 of 9

Limitations of Use:

Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended (1).

Opzelura has a boxed warning regarding serious infections. Serious infections have occurred in patients receiving oral JAK inhibitors and serious lower respiratory tract infections were reported by patients using topical ruxolitinib. Use in active, serious infection should be avoided. Risks and benefits should be carefully considered before using in patients with a history of or at an increased risk for: chronic or recurrent infection, opportunistic infection, or tuberculosis. All patients should be closely monitored for development of infection and treatment interrupted and permanently discontinued as appropriate (1).

Opzelura also carries boxed warnings for mortality and major adverse cardiovascular events (MACE). A higher risk of all-cause mortality, including sudden cardiovascular death was observed in clinical trials of oral JAK inhibitors. Additionally, these clinical trials recorded MACE, which includes fatal cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. The risks and benefits of treatment with Opzelura should be carefully considered before prior to initiating or continuing treatment (1).

The last boxed warnings are regarding malignancies and thrombosis. Lymphoma and other malignancies have been observed in patients treated with oral Janus kinase inhibitors. Non-melanoma skin cancers, including basal cell and squamous cell have occurred in patients treated with Opzelura. Thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis have occurred in patients treated with oral JAK inhibitors used to treat inflammatory conditions (1).

Opzelura has a maximum dose of 60 grams (one tube) per week. The manufacturer notes that it expects typical use to be 3-4 tubes of medication per year (1-2).

The safety and effectiveness of Opzelura in patients less than 12 years of age have not been established (1).

Related policies

Eucrisa

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Section:	Prescription Drugs	Effective Date:	July 1, 2024
Subsection:	Topical Products	Original Policy Date:	October 22, 2021
Subject:	Opzelura	Page:	3 of 9

Opzelura may be considered **medically necessary** if the conditions indicated below are met.

Opzelura may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 12 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Mild to moderate atopic dermatitis (eczema)
 - a. 18 years of age or older
 - i. Inadequate treatment response, intolerance, or contraindication to **ONE** medication in **EACH** of the following categories:
 - 1) Topical calcineurin inhibitor (see Appendix I)
 - 2) **High** potency topical corticosteroid (see Appendix II)
 - ii. Prescriber agrees that treatment will be stopped when signs and symptoms resolve **OR** that the patient will be treated for no longer than 8 weeks at a time
 - b. 12 to 17 years of age
 - i. Inadequate treatment response, intolerance, or contraindication to **ONE** medication in **EACH** of the following categories:
 - 1) Topical calcineurin inhibitor (see Appendix I)
 - 2) A topical corticosteroid (see Appendix II)
 - ii. Prescriber agrees that treatment will be stopped when signs and symptoms resolve **OR** that the patient will be treated for no longer than 8 weeks at a time
 - c. Documented baseline evaluation of the condition using **ONE** of the following scoring tools:
 - i. Investigator's Static Global Assessment (ISGA) score
(e.g., https://www.eczemacouncil.org/assets/docs/Validated-Investigator-Global-Assessment-Scale_vIGA-AD_2017.pdf)
 - ii. Eczema Area and Severity Index (EASI)
(e.g., <https://dermnetnz.org/topics/easi-score/>)

Section:	Prescription Drugs	Effective Date:	July 1, 2024
Subsection:	Topical Products	Original Policy Date:	October 22, 2021
Subject:	Opzelura	Page:	4 of 9

- iii. Patient-Oriented Eczema Measure (POEM)
(e.g., <https://jamanetwork.com/data/Journals/DERM/11776/dea40003f1.png>)
 - iv. Scoring Atopic Dermatitis (SCORAD) index
(e.g., <https://dermnetnz.org/topics/scorad/>)
2. Nonsegmental vitiligo
- a. Inadequate treatment response, intolerance, or contraindication to **ONE** medication in **EACH** of the following categories:
 - i. Topical calcineurin inhibitor (see Appendix I)
 - ii. A topical corticosteroid (see Appendix II)
 - b. Other causes of depigmentation (e.g., tinea versicolor, albinism, age spots, melasma, piebaldism, hypopigmented mycosis, pityriasis alba, etc.) have been ruled out

AND ALL of the following for **ALL** indications:

- a. Patient is **NOT** immunocompromised
- b. Prescriber agrees to evaluate patient for latent and active TB infections prior to and during treatment with Opzelura therapy, as appropriate
- c. **NO** active bacterial, invasive fungal, viral, or other opportunistic infections
- d. **NOT** used in combination with potent immunosuppressants, such as azathioprine or cyclosporine
- e. Prescriber has assessed the patient's risk factors for malignancy and major adverse cardiovascular events (MACE) (e.g., advanced age, smoking history, etc.) and determined that treatment with Opzelura therapy is appropriate
- f. **NO** dual therapy with Eucrisa (crisaborole)

Prior – Approval *Renewal* Requirements

Age 12 years of age or older

Diagnoses

Patient must have **ONE** of the following:

- 1. Atopic dermatitis (eczema)
 - a. Documented improvement using **ONE** of the following scores:
 - i. ISGA – decrease from baseline by at least 2 points

Section:	Prescription Drugs	Effective Date:	July 1, 2024
Subsection:	Topical Products	Original Policy Date:	October 22, 2021
Subject:	Opzelura	Page:	5 of 9

(e.g., https://www.eczemacouncil.org/assets/docs/Validated-Investigator-Global-Assessment-Scale_vIGA-AD_2017.pdf)

- ii. EASI – decrease from baseline by at least 75%
(e.g., <https://dermnetnz.org/topics/easi-score/>)
 - iii. POEM – decrease from baseline by at least 3 points
(e.g., <https://jamanetwork.com/data/Journals/DERM/11776/dea40003f1.png>)
 - iv. SCORAD – decrease from baseline by at least 50%
(e.g., <https://dermnetnz.org/topics/scorad/>)
- b. Prescriber agrees that treatment will be stopped when signs and symptoms resolve **OR** that the patient will be treated for no longer than 8 weeks at a time
2. Nonsegmental vitiligo
- a. Condition has improved or stabilized

AND ALL of the following for **ALL** indications:

- a. Patient is **NOT** immunocompromised
- b. **NO** active bacterial, invasive fungal, viral, or other opportunistic infections
- c. **NOT** used in combination with potent immunosuppressants, such as azathioprine or cyclosporine
- d. Prescriber has assessed the patient's risk factors for malignancy and major adverse cardiovascular events (MACE) (e.g., advanced age, smoking history, etc.) and determined that treatment with Opzelura therapy is appropriate
- e. **NO** dual therapy with Eucrisa (crisaborole)

Policy Guidelines

Pre – PA Allowance

None

Prior - Approval Limits

Atopic dermatitis

Quantity 4 tubes
Duration 12 months

Nonsegmental vitiligo

Quantity 12 tubes
Duration 12 months

Section:	Prescription Drugs	Effective Date:	July 1, 2024
Subsection:	Topical Products	Original Policy Date:	October 22, 2021
Subject:	Opzelura	Page:	6 of 9

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Opzelura (ruxolitinib) is a topical JAK inhibitor indicated for the treatment of mild to moderate atopic dermatitis and nonsegmental vitiligo in patients 12 years of age and older. Opzelura carries boxed warnings regarding infection, mortality, malignancy, MACE, and thrombosis. Patients should be carefully evaluated for risks of benefits of treatment before initiating or continuing therapy. The safety and effectiveness of Opzelura in patients less than 12 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Opzelura while maintaining optimal therapeutic outcomes.

References

1. Opzelura [package insert]. Wilmington, DE: Incyte Corporation.; September 2023.
2. Opzelura (ruxolitinib) cream FDA Approval Call; Incyte Manufacturer Website; https://s21.q4cdn.com/114423841/files/doc_presentations/2021/Rux-Cream-approval-call_v31_no-notes.pdf; September 22, 2021.

Policy History

Date	Action
October 2021	Addition to PA
December 2021	Annual review
July 2022	Per PI update – addition of vitiligo to criteria noting that it is excluded from coverage
September 2022	Annual review
October 2022	Per FEP revised TB requirement to “Prescriber agrees to evaluate patient for latent and active TB infections prior to and during treatment with Opzelura therapy, as appropriate”
December 2022	Annual review
January 2023	Changed Appendix 2 and moved fluradrenolide tape to very high potency
March 2023	Annual review

5.90.050

Section: Prescription Drugs

Effective Date: July 1, 2024

Subsection: Topical Products

Original Policy Date: October 22, 2021

Subject: Opzelura

Page: 7 of 9

September 2023 Annual review and reference update. Per SME, added indication of nonsegmental vitiligo

June 2024 Annual review and reference update

[Keywords](#)

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 13, 2024 and is effective on July 1, 2024.

Section: Prescription Drugs**Effective Date:** July 1, 2024**Subsection:** Topical Products**Original Policy Date:** October 22, 2021**Subject:** Opzelura**Page:** 8 of 9**Appendix 1**

Relative Potency of Topical Calcineurin Inhibitors		
Drug	Dosage Form	Strength
<i>Medium Potency</i>		
Tacrolimus	Ointment	0.1%
<i>Low Potency</i>		
Tacrolimus	Ointment	0.03%
Pimecrolimus	Cream	1%

Appendix 2

Relative Potency of Selected Topical Corticosteroids		
Drug	Dosage Form	Strength
<i>Very high Potency</i>		
Augmented betamethasone dipropionate	Ointment, Gel	0.05%
Clobetasol propionate	Cream, Ointment	0.05%
Diflorasone diacetate	Ointment	0.05%
Flurandrenolide	Tape	4 mcg/cm ²
Halobetasol propionate	Cream, Ointment	0.05%
<i>High Potency</i>		
Amcinonide	Cream, Lotion, Ointment	0.1%
Augmented betamethasone dipropionate	Cream, Lotion	0.05%
Betamethasone dipropionate	Cream, Ointment	0.05%
Betamethasone valerate	Ointment	0.1%
Desoximetasone	Cream, Ointment	0.25%
	Gel	0.05%
Diflorasone diacetate	Cream, Ointment	0.05%
	(emollient base)	
Fluocinonide	Cream, Ointment, Gel	0.05%
Halcinonide	Cream, Ointment	0.1%
Triamcinolone acetonide	Cream, Ointment	0.5%
<i>Medium Potency</i>		
Betamethasone dipropionate	Lotion	0.05%

5.90.050

Section: Prescription Drugs

Effective Date: July 1, 2024

Subsection: Topical Products

Original Policy Date: October 22, 2021

Subject: Opzelura

Page: 9 of 9

Betamethasone valerate	Cream	0.1%
Clocortolone pivalate	Cream	0.1%
Desoximetasone	Cream	0.05%
Fluocinolone acetonide	Cream, Ointment	0.025%
Flurandrenolide	Cream, Ointment, Lotion	0.05%
Fluticasone propionate	Cream	0.05%
	Ointment	0.005%
Hydrocortisone butyrate	Ointment, Solution	0.1%
Hydrocortisone valerate	Cream, Ointment	0.2%
Mometasone furoate	Cream, Ointment, Lotion	0.1%
Prednicarbate	Cream, Ointment	0.1%
Triamcinolone acetonide	Cream, Ointment, Lotion	0.025%
	Cream, Ointment, Lotion	0.1%
<i>Low Potency</i>		
Alclometasone dipropionate	Cream, Ointment	0.05%
Desonide	Cream	0.05%
Fluocinolone acetonide	Cream, Solution	0.01%
Hydrocortisone	Lotion	0.25%
	Cream, Ointment, Lotion, Aerosol	0.5%
	Cream, Ointment, Lotion, Solution	1%
	Cream, Ointment, Lotion	2.5%
Hydrocortisone acetate	Cream, Ointment	0.5%
	Cream, Ointment	1%